Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3607-3612

  DeFronzo, Ralph A ^a,b   Tripathy, Devjit ^a,b   Schwenke, Dawn C ^c,d   Banerji, Mary Ann ^e   Bray, George A ^f   Buchanan, Thomas A ^g   Clement, Stephen C ^h   Henry, Robert R ^i,j   Kitabchi, Abbas E ^k   Mudaliar, Sunder ^i,j   Ratner, Robert E ^l   Stentz, Frankie B ^k   Musi, Nicolas ^a,b   Reaven, Peter D ^b   Gastaldelli, Amalia ^a,b,m  

^a Texas Diabetes Institute   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^l MEDSTAR RESEARCH INSTITUTE   (United States)

^m INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK;

EID: 84891845753     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0520     Document Type: Article

References (36)

1. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007;78:305-312
2. Edelstein SL, KnowlerWC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46:701-710
3. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
4. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
5. Knowler WC, Hamman RF, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-1156
6. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-522
7. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
8. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
9. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetesmellitus (CANOE trial): a doubleblind randomised controlled study. Lancet 2010;376:103-111
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetesmellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077
11. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-1614
12. Defronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 2009;9:17
13. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA; San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31-39
14. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Betacell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500
15. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55: 1430-1435
16. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-1139
17. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292: E871-E883
18. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
19. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
20. Abdul-Ghani MA, Molina-CarrionM, Jani R, Jenkinson C, Defronzo RA. Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 2008;45:147-150
21. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association;National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752
22. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-1268
23. Flegal KM, CarrollMD, Kit BK,Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307: 491-497
24. Centers for Disease Control and Prevention. 2011. National Diabetes Fact Sheet [Internet]. Available fromwww.cdc.gov/diabetes/pubs/pdf/ndfs-2011. Accessed 6 August 2013
25. Abdul-Ghani MA, Williams K,DeFronzo R, Stern M. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 2006;29:1613-1618
26. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 2009;32:281-286
27. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-478
28. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
29. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
30. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514
31. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803
32. Xiang AH, Peters RK, Kjos SL, et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 2004;89:2846-2851
33. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coordinate changes in plasma glucose and pancreatic beta-cell function in Latino women at high risk for type 2 diabetes. Diabetes 2006;55:1074-1079
34. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
35. Nathan DM, Davidson MB, DeFronzo RA, et al.; American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759
36. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795